Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib maintenance monotherapy in platinum-sensitive relapsed non-germline BRCA-mutated ovarian cancer
2017-002767-17Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Oct 2017; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2017-002767-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002767-17.